Powered by
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

IV OCR-002 statistically significantly normalized ammonia faster than standard of care

Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms

Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for IV OCR-002

Company presentation scheduled for today, March 8, 2017 at 11:20 AM ET

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX),

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox